title: Preoperative oral rofecoxib does not decrease postoperative pain or morphine consumption in patients after radical prostatectomy: a prospective, randomized, double-blinded, placebo-controlled trial.
abstract: OBJECTIVE
  To evaluate the analgesic efficacy of the rofecoxib po before radical prostatectomy.
  
  
  METHODS
  Prospective, randomized, double-blinded, placebo-controlled trial.
  
  
  METHODS
  Teaching hospital.
  
  
  METHODS
  Anesthetic management was standardized. Patients received either a 50-mg rofecoxib capsule or a placebo capsule po 1 hour before induction of anesthesia.
  
  
  RESULTS
  Patient-generated 10-cm visual analog scale (VAS) scores for pain were assessed at 1, 2, 4, 6, 8, and 24 hours after surgery. Morphine consumption was recorded from a patient-controlled analgesia device at the same time. A patient-generated overall pain relief score was obtained at 24 hours after surgery. We were unable to detect any differences between study groups with respect to postoperative morphine consumption, VAS score, or overall pain relief score.
  
  
  CONCLUSIONS
  When rofecoxib is used po in maximum recommended doses before surgery, it does not provide significant analgesia that results in reduction in pain scores or analgesic requirements for patients after radical prostatectomy.
authors.affiliation: Department of Anesthesiology and Surgery, Washington University School of Medicine, St Louis, MO 63110, USA. jeffrey_j_huang@hotmail.com
authors.forename: J J
authors.initials: JJ
authors.lastname: Huang
authors.forename: A
authors.initials: A
authors.lastname: Taguchi
authors.forename: H
authors.initials: H
authors.lastname: Hsu
authors.forename: G L
authors.initials: GL
authors.lastname: Andriole
authors.forename: A
authors.initials: A
authors.lastname: Kurz
mesh_terms: D000368:Aged; D016058:Analgesia, Patient-Controlled; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000627:therapeutic use*; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D007527:Isoenzymes; D007783:Lactones / Q000627:therapeutic use*; D008297:Male; D008565:Membrane Proteins; D008875:Middle Aged; D009020:Morphine / Q000008:administration & dosage / Q000627:therapeutic use*; D010147:Pain Measurement; D010149:Postoperative Pain / Q000188:drug therapy / Q000517:prevention & control*; D011446:Prospective Studies; D011451:Prostaglandin-Endoperoxide Synthases; D011468:Prostatectomy; D013450:Sulfones
chemical_list: D000701:Analgesics, Opioid; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D007783:Lactones; D008565:Membrane Proteins; D013450:Sulfones; C116926:rofecoxib; D009020:Morphine; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases